Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase 1b Study of BCL-XL Degrader DT2216 in Combination With Weekly Paclitaxel in Recurrent Platinum-resistant Ovarian Cancer

NCT06964009 is registered in ClinicalTrials.gov with Elizabeth Stover, MD, PhD as lead sponsor.

NCT NCT06964009
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT06964009 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase 1b Study of BCL-XL Degrader DT2216 in Combination With Weekly Paclitaxel in Recurrent Platinum-resistant Ovarian Cancer
Lead sponsor
Elizabeth Stover, MD, PhD
Phase
Phase 1
Overall status
Recruiting
Start date
September 22, 2025
Completion date
December 31, 2028
Enrollment
30 (estimated)
Sites
3

Conditions

As the registry lists them; a condition with its own page is linked.

ovarian cancer, ovarian carcinoma, recurrent ovary cancer, recurrent platinum-resistant ovarian carcinoma